2024 annual financial data
Regeneron Pharmaceuticals 2024 Operating margin
Regeneron Pharmaceuticals 2024 operating margin with verified reported values.
Direct answer
Operating margin was 28.1%.
Operating income was 3,990,700,000 USD and net income was 4,412,600,000 USD.
Operating cash flow was 4,420,500,000 USD.
Get free Regeneron Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 14,202,000,000 USD
- Operating income
- 3,990,700,000 USD
- Net income
- 4,412,600,000 USD
- Operating cash flow
- 4,420,500,000 USD